Literature DB >> 17234259

Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.

Yunfeng Fu1, Dafeng Ye, Huaizeng Chen, Weiguo Lu, Feng Ye, Xing Xie.   

Abstract

OBJECTIVE: Paclitaxel sensitivity has recently been associated with the spindle checkpoint. The aim of our study is to investigate the status of spindle checkpoint and the alteration of its major components in phenotype with acquired paclitaxel resistance in ovarian carcinoma.
METHODS: A paclitaxel-resistant ovarian carcinoma cell line, SKOV3-TR30, with the resistant ability of 27-fold greater than its parental cell line, was derived from SKOV3 cell line. The competence of spindle checkpoint and the expression of the major spindle checkpoint proteins (BubR1 and Mad2) in SKOV3-TR30 cells were investigated.
RESULTS: Mitotic index and flow cytometric analysis revealed that SKOV3-TR30 cells were not arrested in M phase in contrast to SKOV3, which showed a clear mitotic arrest in the presence of paclitaxel or nocodazole. The expressions of securin and cyclin B in SKOV3-TR30 cells were significantly lower than those in SKOV3 cells, indicating the premature degradation of APC substrates in SKOV3-TR30 cells in response to spindle damagers. Chromosome spread analysis showed increased rate of premature sister chromatid segregation in SKOV3-TR30 cells. The expression of spindle checkpoint protein BubR1 was evidently lower in SKOV3-TR30 cells than that in SKOV3 cells. However, there was no significant difference in Mad2 expression between SKOV3-TR30 and SKOV3 cells.
CONCLUSIONS: This study demonstrates that weakened spindle checkpoint with reduced expression of BubR1, but not Mad2, is associated with acquired paclitaxel resistance in ovarian carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17234259     DOI: 10.1016/j.ygyno.2006.10.061

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  23 in total

1.  Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells.

Authors:  Aniek Janssen; Geert J P L Kops; René H Medema
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-23       Impact factor: 11.205

2.  BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma.

Authors:  Ben Davidson; Dag Andre Nymoen; Bente Vilming Elgaaen; Anne Cathrine Staff; Claes G Tropé; Janne Kærn; Reuven Reich; Thea E Hetland Falkenthal
Journal:  Virchows Arch       Date:  2014-04-23       Impact factor: 4.064

Review 3.  Mitotic checkpoint defects: en route to cancer and drug resistance.

Authors:  Sinjini Sarkar; Pranab Kumar Sahoo; Sutapa Mahata; Ranita Pal; Dipanwita Ghosh; Tanuma Mistry; Sushmita Ghosh; Tanmoy Bera; Vilas D Nasare
Journal:  Chromosome Res       Date:  2021-01-06       Impact factor: 5.239

4.  Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer.

Authors:  Yalcin Cirak; Yavuz Furuncuoglu; Ozlem Yapicier; Suleyman Alici; Andac Argon
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer.

Authors:  Song-Fa Zhang; Xin-Yu Wang; Zhi-Qin Fu; Qiao-Hua Peng; Jian-Yang Zhang; Feng Ye; Yun-Feng Fu; Cai-Yun Zhou; Wei-Guo Lu; Xiao-Dong Cheng; Xing Xie
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

6.  Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells.

Authors:  J Bargiela-Iparraguirre; L Prado-Marchal; N Pajuelo-Lozano; B Jiménez; R Perona; I Sánchez-Pérez
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Gradual reduction of BUBR1 protein levels results in premature sister-chromatid separation then in aneuploidy.

Authors:  Elodie Bohers; Nasrin Sarafan-Vasseur; Aurélie Drouet; Marianne Paresy; Jean-Baptiste Latouche; Jean-Michel Flaman; Richard Sesboüé; Thierry Frebourg
Journal:  Hum Genet       Date:  2008-10-19       Impact factor: 4.132

8.  Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest.

Authors:  Samuel C McNeely; Alex C Belshoff; B Frazier Taylor; Teresa W-M Fan; Michael J McCabe; Allan R Pinhas; J Christopher States
Journal:  Toxicol Appl Pharmacol       Date:  2008-02-05       Impact factor: 4.219

9.  BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers.

Authors:  Y-K Lee; E Choi; M A Kim; P-G Park; N-H Park; H Lee
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

10.  The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: a retrospective clinical study.

Authors:  Xinyu Wang; Yajuan Fu; Xiaoduan Chen; Jing Ye; Bingjian Lü; Feng Ye; Weiguo Lü; Xing Xie
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-20       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.